

Docket No.: NUTRI.025NP

Customer No. 20,995

INFORMATION DISCLOSURE STATEMENT


Applicant : Juturu, et al.
App. No : 10/509,487
Filed : September 27, 2004
For : CHROMIUM COMPOSITIONS AND
METHODS FOR USING THE SAME FOR
INHIBITING DRUG-INDUCED INSULIN
RESISTANCE
Examiner : Fay, Zohreh A.
Art Unit : 1618

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

September 13, 2005

(Date)


Mallery K. de Merlier, Reg. No. 51,609

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is an Information Disclosure Statement by Applicant (PTO/SB/08 equivalent) listing 23 references to be considered by the Examiner. Also enclosed are 13 copies of foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required. If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: Sept. 13, 2005

By: 

Mallery K. de Merlier
Registration No. 51,609
Attorney of Record
Customer No. 20,995
(619) 235-8550

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application No. 10/509,487
 Filing Date September 27, 2004
 First Named Inventor Vijaya Juturu
 Art Unit 1618
 Examiner Fay, Zohreh A.
 Attorney Docket No. NUTRI.025NP

SHEET 1 OF 2

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
/C.S./	1	Re. 33,988	07-07-1992	Evans	
	2	4,315,927	02-16-1982	Evans	
	3	4,954,492	09-04-1990	Jensen	
	4	5,087,623	02-11-1992	Boynton et al.	
	5	5,087,624	02-11-1992	Boynton et al.	
	6	5,175,156	12-29-1992	Boynton	
	7	5,194,615	03-16-1993	Jensen	
	8	5,789,401	08-04-1998	McCarty	
	9	5,929,066	07-27-1999	McCarty	
/C.S./	10	6,329,361	12-11-2001	McCarty	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
/C.S./	11	Anderson (1986) Chromium metabolism and its role in disease processes in man. Clin. Psychol. Biochem. 4:31-41.	
	12	Anderson et al. (1997) Lack of toxicity of chromium chloride and picolinate in rats. J. Am. Coll. Nutr. 16(3):273-279.	
	13	Boyle et al. (1977) Chromium depletion in the pathogenesis of diabetes and atherosclerosis. Southern Med. J. 70(12):1449-1453.	
	14	Davis et al. Effects of over-the-counter drugs on chromium retention and urinary excretion in rats. J. Nutrition Res. 15(2):202-210.	
	15	DeFronzo et al. Glucose Clamp Technique: A method for quantifying insulin secretion and resistance. Am. J. Physiol. E214-E223.	
	16	Dorfgliner (2001) Metabolic effects of implantable steroid contraceptives for women. Contraception 65 47-62.	
/C.S./	17	Jula et al. (2002) Effects of diet and simvastatin on serum lipids, insulin, and antioxidants in hypercholesterolemic Men. JAMA 287(5):598-605.	

Examiner Signature /Christopher Stone/

Date Considered 07/02/2008

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/509,487
	Filing Date	September 27, 2004
	First Named Inventor	Vijaya Juturu
	Art Unit	1618
(Multiple sheets used when necessary)	Examiner	Fay, Zohreh A.
SHEET 2 OF 2	Attorney Docket No.	NUTRI.025NP

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
/C.S./	18	Julius et al. (2001) Antihypertensive treatment of patients with diabetes and hypertension. Am. J. Hypertens. 14:310S-316S, 313S (2001).	
/C.S./	19	Kamath et al. (1997) Absorption, retention and urinary excretion of chromium-51 in rats pretreated with indomethacin and dosed with dimethylprostaglandin E2, misoprostol or prostacyclin. J. Nutr. 127:478-482.	
/C.S./	20	Monster, et al. (2001) Oral contraceptive use and hormone replacement therapy are associated with microalbuminuria. Arch Intern Med. 161:2000-2005.	
/C.S./	21	Peterson (2002) Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Danish Medical Bulletin. 49:43-60.	
/C.S./	22	Present Knowledge in Nutrition, Fifth edition (1984, the Nutrition Foundation, Washington, DC) pages 571-586.	
/C.S./	23	Recommended Daily Allowances (1980) Ninth Revised Edition, The National Academy of Sciences, pages 159-161.	

1926666
091305

Examiner Signature	/Christopher Stone/	Date Considered	07/02/2008
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

T¹ - Place a check mark in this area when an English language Translation is attached.